Latest Helixmith News & Updates

See the latest news and media coverage for Helixmith. We track all announcements, press releases, and industry mentions in real time, all in one place.

Helixmith

Gene therapy development company

helixmith.com

Headquarters: Seoul, South Korea
Founded year: 1996
Company type: Public company
Number of employees: 50–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Helixmith

In short: Helixmith secured ₩4.75 billion in government funding for cell therapy manufacturing and initiated a new Phase 3 trial for Engensis.

Company announcements

3 October 2022 Helixmith

Helixmith announces CEO presentation on ALS program DART

Dr. Sunyoung Kim presents at 2022 Cell & Gene Meeting and BIO-Europe. DART investigates HGF/c-Met via plasmid DNA, AAV, and antibodies in parallel for ALS treatment.

8 September 2022 Helixmith

Helixmith announces topline results from Phase 2A ALS study

Engensis high dose with repeated treatments is safe and well-tolerated. Primary safety endpoint achieved; no serious adverse events related to drug.

3 August 2022 Helixmith

Helixmith announces topline results from TADIOS COVID-19 study

TADIOS proved safe and well-tolerated. IL-1RA levels decreased significantly, fatigue improved versus placebo. Study involved 100 subjects in India.

3 May 2022 Helixmith

Helixmith announces VM202 presentation at NYAS Advances in Pain Meeting

Dr. John A. Kessler presents scientific basis and Phase 3 results for VM202 in painful diabetic peripheral neuropathy on May 3, 2022. VM202 shows significant pain reduction and safety.

Media coverage

July 31 Investing.com

Helixmith Co Ltd (084990)

084990 Financial Summary A brief financial summary of Helixmith Co Ltd as well as the most significant critical numbers from each of its financial reports...

June 24 Korea Biomed

Helixmith secures ₩4.75 bil. in government funding over 5 years

Helixmith is accelerating the digital transformation of manufacturing and quality control processes for cell and gene therapies (CGTs).The company said Wednesday that it has been...

March 20 Barchart

Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals

The Key Amyotrophic Lateral Sclerosis Companies in the market include - Amylyx Pharmaceuticals, Sanofi, Brainstorm Cell Therapeutics, AI Therapeutics, Ionis, Biogen, Helixmith, Sanofi, Denali Therapeutics...

February 10 Pharmaphorum

Helixmith starts new trial of diabetic neuropathy gene therapy

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started...

Never miss news about Helixmith

Track Helixmith and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Helixmith competitors & trending companies

Browse news for competitors to Helixmith and other trending companies.